Importantly, a recent study reported that the MAO-B inhibitor, selegiline, reduced subcutaneous and visceral adiposity as well as inflammation of white adipose tissue in a rat model of diet-induced obesity (with high-fat and high-sucrose diet); these effects strongly suggest a beneficial role of MAO inhibitors as an adjuvant therapy in patients with obesity, metabolic syndrome, and type 2 diabetes [74]. Here, MAOB is linked to obesity due to melanocortin 4 receptor deficiency.